Madelon N.M. van der Aa

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

Lucie C. Kompier, Irene Lurkin, Madelon N.M. van der Aa et al. · PLoS ONE · 2010 · 314 citations · Full text

Medicine, Oncology, Urology +17

A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage

Bas W.G. van Rhijn, Theodorus van der Kwast, Sultan S. Alkhateeb et al. · European Urology · 2011 · 191 citations

Medicine, Oncology, Urology +14

Prediction of Progression of Non–Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study

Maximilian Burger, Madelon N.M. van der Aa, Johanna M.M. van Oers et al. · European Urology · 2008 · 178 citations

Medicine, Oncology, Urology +16

A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine

Johanna M.M. van Oers, Irene Lurkin, Antonius J.A. van Exsel et al. · Clinical Cancer Research · 2005 · 162 citations

Medicine, Molecular Genetics, Oncology +17

Cystoscopy Revisited as the Gold Standard for Detecting Bladder Cancer Recurrence: Diagnostic Review Bias in the Randomized, Prospective CEFUB Trial

Madelon N.M. van der Aa, Ewout W. Steyerberg, Chris H. Bangma et al. · The Journal of Urology · 2009 · 126 citations

Medicine, Oncology, Urology +11